Preventive effect of prostaglandin E1 on contrast medium-induced nephropathy in patients with coronary disease combined with diabetes mellitus
10.3760/cma.j.issn.0254-9026.2011.10.010
- VernacularTitle:脂质体携载前列腺素E1对冠心病合并糖尿病患者发生造影剂肾病的预防作用
- Author:
Li ZHU
;
Zhongbao RUAN
;
Yigang YIN
;
Ruzhu WANG
;
Jie LIN
;
Yin REN
;
Ming CHEN
;
Bin WANG
;
Gecai CHEN
;
Linlin GAO
;
Junguo ZHU
- Publication Type:Journal Article
- Keywords:
Prostaglandin E1;
Coronary disease;
Diabetes mellitus,type 2;
Contrast media
- From:
Chinese Journal of Geriatrics
2011;30(10):830-832
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study whether prostaglandin E1 (LipoPGE1) could prevent contrast medium-induced nephropathy (CIN) in patients with coronary heart disease (CHD) plus diabetes mellitus type 2 (DM).Methods Total 198 CHD patients with DM received coronary angiography (CAG) or PCI were randomly divided into PGE1 group and control group.All patients received routine treatment,and the PGE1 group also received 20 ml normal saline and 20 μg PGE1 (intravenous injection,1 time/d) for 10 days.The rate of CIN and the level of serum urea nitrogen (BUN),creatinine (Scr),cystatin C (Cys C) were measured before and 48 hours and 5 days after contrastmedium administration.Results The level of Scr,BUN and Cys C were lower in PGE1 group [(113.92±54.89)μmmol/ L,(7.85±4.05)mmol/L,(1.38±0.34)mg/L]for 48 hours and[(86.72±35.26)μmmol/L,(6.61 ± 3.09 ) mmol/L,( 1.29 ± 0.29) mg/L]for 5 days than in control group [(129.22±50.18)μmmol/L,(9.26±3.95)mmol/L,(1.56±0.23)mg/L]for 48 hours and[(109.83+31.76)μmmol/ L,(8.07±3.11)mmol/L,(1.37±0.21)mg/L]for 5 days (all P＜0.05).The dose of contrast-medium was positively correlated with the level of Scr and BUN (r=0.74,P＜0.05 and r =0.82,P＜0.01,respectively).The patients' renal function in the PGE1 group was better than in control group after contrast-medium administration (P ＜0.05).BUN and Scr were positively correlated with the volume of contrast-medium (r=0.74,P＜0.05,r=0.82,P＜0.01).Conclusions PGE1 may prevent contrast medium-induced nephropathy in patients with CHD combined with DM.
